Loading
Transferring gut bacteria from patients who responded to immunotherapy has helped some patients who had stopped responding. It is time for a proper large trial.
Two independent phase 1 studies reported that faecal microbiota transplant from checkpoint responders re-sensitised some anti-PD-1-refractory melanoma patients, and a first-line study of donor transplant with checkpoint blockade showed feasibility and encouraging response. The field has stayed in small single-arm studies for years. A randomised trial with a defined donor consortium, standardised product and pre-specified microbiome endpoints would settle whether the effect is real.
Shares Laurence Zitvogel, Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy.
Shares Laurence Zitvogel, Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Renal cell carcinoma.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy, Renal cell carcinoma.
Shares MIMic-01: healthy-donor FMT plus anti-PD-1, first-line melanoma, FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh), Faecal microbiota transplantation for PD-1 non-responders, Renal cell carcinoma.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy, Renal cell carcinoma.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy, Melanoma.
Shares FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Laurence Zitvogel, Faecal microbiota transplantation for PD-1 non-responders, No one can predict who responds to immunotherapy, Renal cell carcinoma.